Amid geopolitical uncertainty and evolving supply chain risks, biologics production is shifting from centralized models toward regional, resilient manufacturing networks. In this episode of Off Script, Samsung Biologics' Jeff Mason discusses how CDMOs are adapting, including the company's first U.S. facility acquisition in Rockville, Maryland. The conversation covers manufacturing redundancy, vertically integrated supply chains, and the future of global production ecosystems.
Amid geopolitical uncertainty and evolving supply chain risks, biologics production is shifting from centralized models toward regional, resilient manufacturing networks. In this episode of Off Script, Samsung Biologics' Jeff Mason discusses how CDMOs are adapting, including the company's first U.S. facility acquisition in Rockville, Maryland. The conversation covers manufacturing redundancy, vertically integrated supply chains, and the future of global production ecosystems.
Share article
Related Content